Claims for Patent: 8,569,348

Summary for Patent: 8,569,348

Title:	Compounds, compositions, and methods for preventing metastasis of cancer cells
Abstract:	Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.
Inventor(s):	Shalwitz; Robert (Bexley, OH), Peters; Kevin G. (Cincinnati, OH)
Assignee:	Aerpio Therapeutics Inc. (Cincinnati, OH)
Application Number:	12/677,550
Patent Claims:	1. A method for rebducing and/or delaying metastasis in a subject, comprising contacting the subject with an effective amount of a compound having the formula: ##STR00234## wherein R is a substituted or unsubstituted thiazolyl unit having the formula: ##STR00235## R.sup.2, R.sup.3, and R.sup.4 are each independently: i) hydrogen; ii) substituted or unsubstituted C.sub.1-C.sub.6 linear, branched, or cyclic alkyl; iii) substituted or unsubstituted C.sub.2-C.sub.6 linear, branched, or cyclic alkenyl; iv) substituted or unsubstituted C.sub.2-C.sub.6 linear or branched alkynyl; v) substituted or unsubstituted C.sub.6 or C.sub.10 aryl; vi) substituted or unsubstituted C.sub.1-C.sub.9 heteroaryl; vii) substituted or unsubstituted C.sub.1-C.sub.9 heterocyclic; or viii) R.sup.2 and R.sup.3 can be taken together to form a saturated or unsaturated ring having from 5 to 7 atoms; wherein from 1 to 3 atoms can optionally be heteroatoms chosen from oxygen, nitrogen, and sulfur; Z is a unit having the formula: -(L).sub.n-R.sup.1 R.sup.1 is chosen from: i) hydrogen; ii) hydroxyl; iii) amino; iv) substituted or unsubstituted C.sub.1-C.sub.6 linear, branched or cyclic alkyl; v) substituted or unsubstituted C.sub.1-C.sub.6 linear, branched or cyclic alkoxy; vi) substituted or unsubstituted C.sub.6 or C.sub.10 aryl; vii) substituted or unsubstituted C.sub.1-C.sub.9 heterocyclic rings; or viii) substituted or unsubstituted C.sub.1-C.sub.9 heteroaryl rings; L is a linking unit having the formula: -[Q].sub.y[C(R.sup.5aR.sup.5b)].sub.x[Q.sup.1].sub.z[C(R.sup.6aR.sup.6b)]- .sub.w-- Q and Q.sup.1 are each independently: i) --C(O)--; ii) --NH--; iii) --C(O)NH--; iv) --NHC(O)--; v) --NHC(O)NH--; vi) --NHC(O)O--; vii) --C(O)O--; viii) --C(O)NHC(O)--; ix) --O--; x) --S--; xi) --SO.sub.2--; xii) --C(.dbd.NH)--; xiii) --C(.dbd.NH)NH--; xiv) --NHC(.dbd.NH)--; or xv) --NHC(.dbd.NH)NH--; R.sup.5a and R.sup.5b are each independently: i) hydrogen; ii) hydroxy; iii) halogen; iv) C.sub.1-C.sub.6 substituted or unsubstituted linear or branched alkyl; or v) a unit having the formula: --[C(R.sup.7aR.sup.7b)].sub.tR.sup.8 R.sup.7a and R.sup.7b are each independently: i) hydrogen; or ii) substituted or unsubstituted C.sub.1-C.sub.6 linear, branched, or cyclic alkyl; R.sup.8 is: i) hydrogen; ii) substituted or unsubstituted C.sub.1-C.sub.6 linear, branched, or cyclic alkyl; iii) substituted or unsubstituted C.sub.6 or C.sub.10 aryl; iv) substituted or unsubstituted C.sub.1-C.sub.9 heteroaryl; or v) substituted or unsubstituted C.sub.1-C.sub.9 heterocyclic; R.sup.6a and R.sup.6b are each independently: i) hydrogen; or ii) C.sub.1-C.sub.4 linear or branched alkyl; the index n is 0 or 1; the indices t, w and x are each independently from 0 to 4; the indices y and z are each independently 0 or 1; or a pharmaceutically acceptable salt thereof; wherein the cancer is malignant melanoma or lung cancer. 2. A method for reducing and/or delaying metastasis in a subject, comprising contacting the subject with a composition comprising: A) an effective amount of one or more compounds having the formula: ##STR00236## wherein R is a substituted or unsubstituted thiazolyl unit having the formula: ##STR00237## R.sup.2, R.sup.3, and R.sup.4 are each independently: i) hydrogen; ii) substituted or unsubstituted C.sub.1-C.sub.6 linear, branched, or cyclic alkyl; iii) substituted or unsubstituted C.sub.2-C.sub.6 linear, branched, or cyclic alkenyl; iv) substituted or unsubstituted C.sub.2-C.sub.6 linear or branched alkynyl; v) substituted or unsubstituted C.sub.6 or C.sub.10 aryl; vi) substituted or unsubstituted C.sub.1-C.sub.9 heteroaryl; vii) substituted or unsubstituted C.sub.1-C.sub.9 heterocyclic; or viii) R.sup.2 and R.sup.3 can be taken together to form a saturated or unsaturated ring having from 5 to 7 atoms; wherein from 1 to 3 atoms can optionally be heteroatoms chosen from oxygen, nitrogen, and sulfur; Z is a unit having the formula: -(L).sub.n-R.sup.1 R.sup.1 is chosen from: i) hydrogen; ii) hydroxyl; iii) amino; iv) substituted or unsubstituted C.sub.1-C.sub.6 linear, branched or cyclic alkyl; v) substituted or unsubstituted C.sub.1-C.sub.6 linear, branched or cyclic alkoxy; vi) substituted or unsubstituted C.sub.6 or C.sub.10 aryl; vii) substituted or unsubstituted C.sub.1-C.sub.9 heterocyclic rings; or viii) substituted or unsubstituted C.sub.1-C.sub.9 heteroaryl rings; L is a linking unit having the formula: -[Q].sub.y[C(R.sup.5aR.sup.5b)].sub.x[Q.sup.1].sub.z[C(R.sup.6aR.sup.6b)- ].sub.w-- Q and Q.sup.1 are each independently: i) --C(O)--; ii) --NH--; iii) --C(O)NH--; iv) --NHC(O)--; v) --NHC(O)NH--; vi) --NHC(O)O--; vii) --C(O)O--; viii) --C(O)NHC(O)--; ix) --O--; x) --S--; xi) --SO.sub.2--; xii) --C(.dbd.NH)--; xiii) --C(.dbd.NH)NH--; xiv) --NHC(.dbd.NH)--; or xv) --NHC(.dbd.NH)NH--; R.sup.5a and R.sup.5b are each independently: i) hydrogen; ii) hydroxy; iii) halogen; iv) C.sub.1-C.sub.6 substituted or unsubstituted linear or branched alkyl; or v) a unit having the formula: --[C(R.sup.7aR.sup.7b)].sub.tR.sup.8 R.sup.7a and R.sup.7b are each independently: i) hydrogen; or ii) substituted or unsubstituted C.sub.1-C.sub.6 linear, branched, or cyclic alkyl; R.sup.8 is: i) hydrogen; ii) substituted or unsubstituted C.sub.1-C.sub.6 linear, branched, or cyclic alkyl; iii) substituted or unsubstituted C.sub.6 or C.sub.10 aryl; iv) substituted or unsubstituted C.sub.1-C.sub.9 heteroaryl; or v) substituted or unsubstituted C.sub.1-C.sub.9 heterocyclic; R.sup.6a and R.sup.6b are each independently: i) hydrogen; or ii) C.sub.1-C.sub.4 linear or branched alkyl; the index n is 0 or 1; the indices t, w and x are each independently from 0 to 4; the indices y and z are each independently 0 or 1; or a pharmaceutically acceptable salt thereof; and B) an effective amount of one or more chemotherapeutic agents; wherein the cancer is malignant melanoma or lung cancer. 3. A method according to claim 2, wherein the chemotherapeutic agent is chosen from vincristine, vinblastine, vindesine, vinorelbine-5'-noranhydroblastine, irinotecan, topotecan, cisplatin, cyclophosphamide, nitrogen mustard, trimethylene thiophosphoramide, carmustine, busulfan, chlorambucil, belustine, chlomaphazin, dacarbazine, cytosine arabinoside, fluorouracil, methotrexate, mercaptopurine, azathioprime, procarbazine, doxorubicin, bleomycin, dactinomycin, daunorubicin, mithramycin, mitomycin, mytomycin C, daunomycin, azacytidine, amsacrine, melphalan, ifosfamide, mitoxantrone, cis-platin, etoposide, taxol, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; anastrozole; anthramycin; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; sulfate; brequinar sodium; bropirimine; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carubicin hydrochloride; carzelesin; cedefingol; cirolemycin; cladribine; crisnatol mesylate; cytarabine; decitabine; dexormaplatin; dezaguanine; diaziquone; docetaxel; droloxifene; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; etanidazole; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; hydroxyurea; idarubicin hydrochloride; ilmofosine; interleukin II interferon alfa-2a; interferon alfa-2b; interferon alfa-n1; interferon alfa-n3; interferon beta-I a; interferon gamma-I b; iproplatin; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; menogaril; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitosper; mitotane; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; paclitaxel; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; puromycin; pyrazofurin; riboprine; rogletimide; safingol; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; triptorelin; tubulozole hydrochloride; uredepa; vapreotide; verteporfin; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; and zorubicin hydrochloride. 4. A method according to claim 2, wherein the chemotherapeutic agent is chosen from taxol, IL-2, gemcitabine, erlotinib, doxil, irinortecan, and bevacizumab. 5. A method according to claim 1, wherein R.sup.2 is a heteroaryl unit chosen from 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, [1,2,3]triazol-4-yl, [1,2,3]triazol-5-yl, [1,2,4]triazol-4-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, imidazol-4-yl, pyrrol-2-yl, pyrrol-3-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]oxadiazol-5-yl, [1,3,4]oxadiazol-2-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl, isothiazol-3-yl, isothiazol-4yl, isothiazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, [1,2,4]thiadiazol-3-yl, [1,2,4]thiadiazol-5-yl, or [1,3,4]thiadiazol-2-yl. 6. A method according to claim 1, wherein R.sup.4 is chosen from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and tert-butyl; and R.sup.3 is hydrogen. 7. A method according to claim 1, wherein the compound has the formula: ##STR00238## wherein R.sup.2 is methyl or ethyl, R.sup.3 is hydrogen, R.sup.6a is chosen from phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 3-methyl-1,2,4-oxadiazol-5-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, or isoxazol-3-yl. 8. A method according to claim 1, wherein the compound has the formula: ##STR00239## wherein R.sup.4 is methyl, ethyl, phenyl, or thiophen-2-yl, R.sup.6a is chosen from phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 3-methyl-1,2,4-oxadiazol-5-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, or isoxazol-3-yl. 9. A method according to claim 1, wherein the compound has the formula: ##STR00240## or the ammonium salt thereof. 10. A method according to claim 1, wherein the compound has the formula: ##STR00241## and pharmaceutically acceptable salts thereof. 11. A method according to claim 1, wherein the compound is in the form of a salt of a cation chosen from ammonium, sodium, lithium, potassium, calcium, magnesium, bismuth, and lysine. 12. A composition according to claim 2, wherein the compound has the formula: ##STR00242## pharmaceutically acceptable salts thereof. 13. A composition according to claim 2, wherein the compound is in the form of a salt of a cation chosen from ammonium, sodium, lithium, potassium, calcium, magnesium, bismuth, and lysine. 14. A method according to claim 1, wherein the compound is chosen from a compound having the formula: i) ##STR00243## ii) ##STR00244## iii) ##STR00245## the ammonium salt thereof. 15. The method according to claim 1, wherein the compound is chosen from: 4-{(S)-2-[(S)-2-(tert-butoxycarbonylamino)-3-phenylpropanamido]-2-(4-ethy- lthiazol-2-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-[(R)-2-(tert-butoxycarbonylamino)-3-phenylpropanamido]-2-(4-ethy- lthiazol-2-yl)ethyl}phenylsulfamic acid; {1-[1-(4-Ethylthiazol-2-yl)-(S)-2-(4-sulfoaminophenyl)ethylcarbamoyl]-(S)- -2-phenylethyl}methyl carbamic acid tert-butyl ester; {1-[1-(4-Phenylthiazol-2-yl)-(S)-2-(4-sulfoaminophenyl)ethylcarbamoyl]-(S- )-2-phenylethyl}methyl carbamic acid tert-butyl ester; (4((S)-2((S)-2-((tert-Butoxycarbonyl)amino)-3-phenylpropaneamido)-2-(2-ph- enylthiazol-4-yl)ethyl)phenyl)sulfamic acid; 4-((S)-2((S)-2-(Methoxycarbonylamino)-3-phenylpropanamido)-2-(2-ethylthia- zol-4-yl)ethyl)phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-(2-methylth- iazol-4-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-(2-Isopropylthiazol-4-yl)-2-[(S)-2-(methoxycarbonylamino)-3-phen- ylpropan-amido]ethyl}phenylsulfamic acid; 4-{(S)-2-{2-[(4-Chlorophenylsulfonyl)methyl]thiazol-4-yl}-2-[(S)-2-(metho- xy-carbonylamino)-3-phenylpropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[2-(tert-Butylsulfonylmethyl)thiazol-4-yl]-2-[(S)-2-(methoxycarb- onylamino)-3-phenylpropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropionamido]-2-(2-phenylt- hiazole-4-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-[(2-(thioph- en-2-yl)thiazol-4-yl]ethyl}phenylsulfamic acid; 4-{(S)-2-[2-(3-Chlorothiophen-2-yl)thiazol-4-yl]-2-[(S)-2-(methoxycarbony- lamino)-3-phenylpropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-[2-(3-methy- lthiophen-2-yl)thiazol-4-yl]ethyl}phenylsulfamic acid; 4-{[(S)-2-(2-(Furan-2-yl)thiazol-4-yl]-2-[(S)-2-(methoxycarbonylamino)-3-- phenylpropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-[2-(2-methy- lthiazol-4-yl)thiazole-4yl]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-[(2-pyrazin- -2-yl)thiazol-4-yl]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-[2-(6-methy- lpyridin-3-yl)thiazol-4-yl]ethyl}phenylsulfamic acid; 4-((S)-2-((S)-2-acetamido-3-phenylpropanamido)-2-(4-ethylthiazol-2-yl)eth- yl)phenylsulfamic acid; 4-[(S)-2-((S)-2-Acetamido-3-phenylpropanamido)-2-(4-tert-butylthiazol-2-y- l)ethyl]phenylsulfamic acid; 4-{(S)-2((S)-2-Acetamido-3-phenylpropanamido)-2-[4-(thiophen-3-yl)thiazol- -2-yl]ethyl)phenylsulfamic acid; 4-{(S)-2-[(S)-2-(tert-butoxycarbonylamino)-3-methylbutanamido]-2-(4-ethyl- thiazol-2-yl)ethyl}phenylsulfamic acid; (S)-4-{2-[2-(tert-Butoxycarbonyl)acetamide]-2-(4-ethylthiazol-2-yl)ethyl}- -phenylsulfamic acid; 4-{(S)-2-[(S)-2-(tert-Butoxycarbonylamino)-4-methylpentanamido]-2-(4-ethy- lthiazol-2-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(tert-Butoxycarbonylamino)-4-methylpentanamido]-2-[2-(thi- ophen-2-yl)thiazol-4-yl]ethyl}phenylsulfamic acid; (S)-4-{2-[2-(tert-Butoxycarbonyl)amino]acetamido-2-(4-ethylthiazol-2-yl)e- thyl}-phenylsulfamic acid; 4-{(S)-2-(4-Ethylthiazol-2-yl)-2-[(S)-2-(methoxycarbonylamino)-4-methylpe- ntan-amido]ethyl}phenylsulfamic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(methoxycarbonylamino)acetamido]ethyl- }phenyl-sulfamic acid; 4-{(S)-2-(4-Ethylthiazol-2-yl)-2-[(S)-2-(methoxycarbonylamino)-3-methylbu- tanamido]-ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-4-methylpentanamido]-2-[2-(thiophe- n-2-yl)thiazol-4-yl]ethyl}phenylsulfamic acid; [1-(S)-(phenylthiazol-2-yl)-2-(4-sulfoaminophenyl)ethyl]carbamic acid tert-butyl ester; (S)-4-(2-(4-Methylthiazol-2-yl)-2-pivalamidoethyl)phenylsulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-pivalamidoethyl)phenylsulfamic acid; (S)-4-(2-(4-(Hydroxymethyl)thiazol-2-yl)-2-pivalamidoethyl)phenylsulfamic acid; (S)-4-(2-(4-(Ethoxycarbonyl)thiazol-2-yl)-2-pivalamidoethyl)phenyls- ulfamic acid; (S)-4-(2-(4-Phenylthiazol-2-yl)-2-pivalamidoethyl)phenylsulfamic acid; 4((S)-2-(4-(3-Methoxyphenyl)thiazol-2-yl)-2-pivalamidoethyl)phenylsulfami- c acid; 4((S)-2-(4-(2,4-Dimethoxyphenyl)thiazol-2-yl)-2-pivalamidoethyl)ph- enylsulfamic acid; (S)-4-(2-(4-Benzylthiazol-2-yl)-2-pivalamidoethyl)phenylsulfamic acid; (S)-4-(2-Pivalamido-2-(4-(thiophen-2-ylmethyl)thiazol-2-yl)ethyl)phenylsu- lfamic acid; (S)-4-(2-(4-(3-Methoxybenzyl)thiazol-2-yl)-2-pivalamidoethyl)phenylsulfam- ic acid; 4-((S)-2-(4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)thiazol-2-yl)-2-- pivalamidoethyl)-phenylsulfamic acid; (S)-4-(2-(5-Methyl-4-phenylthiazol-2-yl)-2-pivalamidoethyl)phenylsulfamic acid; (S)-4-(2-(4-(Biphen-4-yl)thiazol-2-yl)-2-pivalamidoethyl)phenylsulf- amic acid; (S)-4-(2-tert-Butoxycarbonyl-2-(2-methylthaizol-4-yl)-phenylsul- famic acid; (S)-4-(2-(tert-Butoxycarbonyl)-2-(4-propylthiazol-2-yl)ethyl)-phenylsulfa- mic acid; (S)-4-(2-(tert-Butoxycarbonyl)-2-(4-tert-butylthiazol-2-yl)ethyl- )-phenylsulfamic acid; (S)-4-(2-(tert-Butoxycarbonylamino)-2-(4-(methoxymethyl)thiazol-2-yl)ethy- l)-phenylsulfamic acid; (S)-4-(2-tert-Butoxycarbonylamino)-2-(4-(2-hydroxymethyl)thiazol-2-yl)eth- yl)phenyl-sulfamic acid; (S)-(4-(2-tert-Butoxycarbonylamino)-2-(4-(2-ethoxy-2-oxoethyl)-thiazole-2- -yl)-ethyl)phenylsulfamic acid; (S)-4-(2-(tert-Butoxycarbonylamino)-2-(4-(2-methoxy-2-oxoethyl)thiazol-2-- yl)ethyl)phenylsulfamic acid; (S)-4-(2-(tert-Butoxycarbonylamino)-2-(2-(pivaloyloxy)thiazol-4-yl)ethyl)- phenylsulfamic acid; (S)-4-(2-(tert-Butoxycarbonylamino)-2-(5-phenylthiazol-2-yl)ethyl)-phenyl- sulfamic acid; 4-((S)-2-(tert-Butoxycarbonylamino)-2-(4-(3-(trifluoromethyl)phenyl)thiaz- ol-2-yl)ethyl)-phenylsulfamic acid; (S)-4-(2-(tert-Butoxycarbonylamino)-2-(4-phenylthiazol-2-yl)ethyl)-phenyl- sulfamic acid; (S,S)-2-(2-{2-[2-tert-Butoxycarbonylamino-2-(4-sulfoaminophenyl)ethyl]thi- azol-4-yl}acetylamido)-3-phenylpropionic acid methyl ester; 4-((S)-2-(tert-Butoxycarbonylamino)-2-(4-(thiophen-3-yl)thiazol-2-yl)ethy- l)-phenylsulfamic acid; (S)-4-(2-(Benzo[d]thiazol-2-ylamino)-2-(tert-butoxycarbonyl)ethyl)phenyls- ulfamic acid; {4-[2-(S)-(4-ethylthiazol-2-yl)-2-(2-phenylacetylamido)ethyl]-phenyl}sulf- amic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(2-(2-fluorophenyl)acetamido)e- thyl)phenylsulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(2-(3-fluorophenyl)acetamido)ethyl)pheny- lsulfamic acid; (S)-4-(2-(2-(2,3-Difluorophenyl)acetamido)-2-(4-ethylthiazol-2-yl)ethyl)p- henyl-sulfamic acid; (S)-4-(2-(2-(3,4-Difluorophenyl)acetamido)-2-(4-ethylthiazol-2-yl)ethyl)p- henyl-sulfamic acid; (S)-4-(2-(2-(2-Chlorophenyl)acetamido)-2-(4-ethylthiazol-2-yl)ethyl)pheny- lsulfamic acid; (S)-4-(2-(2-(3-Chlorophenyl)acetamido)-2-(4-ethylthiazol-2-yl)ethyl)pheny- lsulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(2-(3-hydroxyphenyl)acetamido)ethyl)phen- yl-sulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(2-(2-methoxyphenyl)acetamido)ethyl)phen- yl-sulfamic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(3-methoxyphenyl)acetamido]ethyl}-phe- nylsulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(3-phenylpropanamido)ethyl)phenylsulfami- c acid; (S)-4-(2-(2-(3,4-Dimethoxyphenyl)acetamido)-2-(4-ethylthiazol-2-yl- )ethyl)-phenylsulfamic acid; (S)-4-(2-(2-(2,3-Dimethoxyphenyl)acetamido)-2-(4-ethylthiazol-2-yl)ethyl)- -phenylsulfamic acid; (S)-4-(2-(3-(3-Chlorophenyl)propanamido)-2-(4-ethylthiazol-2-yl)ethyl)phe- nyl-sulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(3-(2-methoxyphenyl)propanamido)ethyl)ph- enyl-sulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(3-(3-methoxyphenyl)propanamido)ethyl)ph- enyl-sulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(3-(4-methoxyphenyl)propanamido)ethyl)ph- enyl-sulfamic acid; (S)-4-{2-[2-(4-Ethyl-2,3-dioxopiperazin-1-yl)acetamido]-2-(4-ethylthiazol- -2-yl)ethyl}phenylsulfamic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(5-methyl-2,4-dioxo-3,4-dihydropyrimi- din-1(2H)-yl)acetamido]ethyl}phenylsulfamic acid; (S)-4-[2-(benzo[d][1,3]dioxole-5-carboxamido)-2-(4-ethylthiazol-2-yl)ethy- l]-phenylsulfamic acid; (S)-4-{2-[2-(2,5-Dimethylthiazol-4-yl)acetamido]-2-(4-ethylthiazol-2-yl)e- thyl}-phenylsulfamic acid; (S)-4-{2-[2-(2,4-Dimethylthiazol-5-yl)acetamido]-2-(4-methylthiazol-2-yl)- ethyl}-phenylsulfamic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[3-(thiazol-2-yl)propanamido]ethyl}pheny- lsulfamic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(4-ethylthiazol-2-yl)acetamido]ethyl}- phenyl-sulfamic acid; (S)-(4-(2-(2-(3-Chlorophenyl)acetylamino]-2-(2-(thiophen-2-ylthiazol-4-yl- )ethyl]phenyl)sulfamic acid; 4((S)-2-(2-(3-Methoxyphenyl)acetamido)-2-(2-(thiophen-2-yl)thiazol-4-yl)e- thyl)-phenylsulfamic acid; 4-{(S)-2-(3-Phenylpropanamido)-2-[2-(thiophen-2-yl)thiazol-4-yl]ethyl}-ph- enylsulfamic acid; 4-{(S)-2-(3-(3-Chlorophenyl)propanamido)-2-[2-(thiophen-2-yl)thiazol-4-yl- ]ethyl}-phenylsulfamic acid 4-{(S)-2-[2-(3-Fluorophenyl)acetamido]-2-[2-(thiophen-2-yl)thiazol-4-yl]e- thyl}-phenylsulfamic acid; (S)-4-{2-[2-(3-Methyl-1,2,4-oxadiazol-5-yl)acetamido]-2-(2-phenylthiazol-- 4-yl)ethyl}-phenylsulfamic acid; 4-{(S)-2-[2-(4-ethyl-2,3-dioxopiperazin-1-yl)acetamido]-2-[2-(thiophen-2-- yl)thiazol-4-yl]ethyl}phenylsulfamic acid; (S)-4-(2-(2,3-diphenylpropanamido)-2-(4-ethylthiazol-2-yl)ethyl)phenylsul- famic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(2-methoxyphenyl)-3-phenylpropanamido- ]-ethyl}phenylsulfamic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(3-fluorophenyl)-3-phenylpropanamido]- -ethyl}-phenylsulfamic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(3-methoxyphenyl)-3-phenylpropanamido- ]-ethyl}phenylsulfamic acid; 4-{(S)-2-(4-ethylthiazol-2-yl)-2-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-3-phe- nylpropan-amido]ethyl}phenylsulfamic acid; (S)-4-[2-(4-ethylthiazol-2-yl)-2-(4-oxo-4-phenylbutanamido)-ethyl]phenyls- ulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(5-methyl-4-oxohexanamido)ethyl)phenylsu- lfamic acid; (S)-4-{2-[4-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-4-oxobutanamido]-- 2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; (S)-4-{2-[4-(2,3-Dimethoxyphenyl)-4-oxobutanamido]-2-(4-ethylthiazol-2-yl- )ethyl}-phenylsulfamic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[4-oxo-4-(pyridin-2-yl)butanamido]ethyl}- -phenyl-sulfamic acid; (S)-4-{2-[4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-oxobutanamido]-2-(4-e- thylthiazol-2-yl)ethyl}phenylsulfamic acid; (S)-4-[2-(4-tert-butoxy-4-oxobutanamido)-2-(4-ethylthiazol-2-yl)ethyl]phe- nylsulfamic acid; (S)-4-[2-(4-ethoxy-4-oxobutanamido)-2-(4-ethylthiazol-2-yl)ethyl]phenylsu- lfamic acid; (S)-4-(2-(3-benzylureido)-2-(4-ethylthiazol-2-yl)ethyl)phenylsulfamic acid; 4-{(S)-2-(3-benzylureido)-2-[2-(thiophen-2-yl)thiazol-4-yl]ethyl}ph- enylsulfamic acid; {4-(S)-[2-phenylmethanesulfonylamino-2-(2-thiophen-2-ylthiazol-4-yl)ethyl- ]phenyl}-sulfamic acid; (S)-(4-(2((2-Methylthiazol-4-yl)methylsulfonamido)-2-(2-(2(thiophen-2-yl)- thiazol-4-yl)ethyl)phenyl)sulfamic acid; {4-(S)-[2-Phenylmethanesulfonylamino-2-(2-ethylthiazol-4-yl)ethyl]phenyl}- -sulfamic acid; (S)-(4-(2-(2-Ethylthiazol-4-yl)-2((3-ethoxyphenyl)methylsulfonamido)ethyl- )-phenyl)sulfamic acid; (S)-4-{[1-(2-Ethylthiazol-4-yl)-2-(4-sulfoaminophenyl)ethylsulfamoyl]meth- yl}-benzoic acid methyl ester; (S)-(4-(2-(2-Ethylthiazol-4-yl)-2((1-methyl-1H-imidazol-4-yl)methylsulfon- amido)-ethyl)phenyl)sulfamic acid; 4-{(S)-2-[2-(Thiophen-2-yl)thiazol-4-yl]-2-(2,2,2-trifluoroethylsulfonami- do)-ethyl}phenylsulfamic acid; {4-(S)-[2-(Phenylethanesulfonylamino)-2-(2thiophen-2-ylthiazol-4-yl)ethyl- ]-phenyl}sulfamic acid; {4-(S)-[3-(Phenylpropanesulfonylamino)-2-(2thiophen-2-ylthiazol-4-yl)ethy- l]-phenyl}sulfamic acid; (S)-{4-[2-(4-Methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonylamino)-2-(- 2-thiophen-2-ylthiazol-4-yl)ethyl]phenyl}sulfamic acid; 4-{(S)-2-(4-acetamidophenylsulfonamido)-2-[2-(thiophen-2-yl)thiazol-4-yl]- ethyl}phenylsulfamic acid; (S)-4-(2-(2-phenylthiazol-4-yl)2(4-(methoxycarbonyl)thiazole-5-ylamino)-e- thyl)phenylsulfamic acid; 4-{(S)-2-(2-cyclopropylthiazol-4-yl)-2-[4-(3-methoxyphenyl)-thiazol-2-yla- mino]ethyl}phenylsulfamic acid; (S)-4-(2-(4-((2-Methoxy-2-oxoethyl)carbamoyl)thiazol-5-ylamino)2-(2-ethyl- thiazol-4-yl)ethyl)phenylsulfamic acid; (S)-4-(2-{5-[1-N-(2-Methoxy-2-oxoethylcarbamoyl)-1-H-indol-3-yl]oxazol-2-- ylamino}-2-(2-methylthiazol-4-yl)ethyl)phenylsulfamic acid; 4-((S)-2-(5-(2-Methoxyphenyl)oxazol-2-ylamino)-2-(2-methylthiazol-4-yl)et- hyl)phenylsulfamic acid; 4-((S)-2-(5)-1-(tert-Butoxycarbonyl)-2-phenylethyl)oxazole-2-ylamino)-2-(- 2-methylthiazole-4-yl)ethyl)phenylsulfamic acid; (S)-{4-{2-[5-(4-Methoxycarbonyl)phenyl]oxazol-2-ylamino}-2-(2-methylthiaz- ol-4-yl)ethyl}phenylsulfamic acid; (S)-4-(2-(5-(3-Methoxybenzyl)oxazole-2-ylamino)-2-(2-methylthiazole-4-yl)- ethyl)phenylsulfamic acid; (S)-4-(2-(2-Methylthiazole-4-yl)2-(5-phenyloxazole-2-ylamino)ethyl)phenyl- sulfamic acid; 4((S)-2-(2-Cyclopropylthiazol-4-yl)-2-(4-(3-methoxyphenyl)thiazol-2-ylami- no)ethyl)-phenylsulfamic acid; (S)-4-(2-(2-Cyclopropylthiazol-4-yl)-2-(4-(4-fluorophenyl)thiazol-2-ylami- no)-ethyl)phenylsulfamic acid; 4((S)-2-(2-Cyclopropylthiazol-4-yl)-2-(4-(2-methoxyphenyl)thiazol-2-ylami- no)-ethyl)phenylsulfamic acid; 4((S)-2-(2-Cyclopropylthiazol-4-yl)-2-(4-(2,4-difluorophenyl)thiazol-2-yl- amino)-ethyl)phenylsulfamic acid; (S)-4-(2-(4-(3-Methoxybenzyl)thiazol-2-ylamino)-2-(2-cyclopropylthiazol-4- -yl)ethyl)phenylsulfamic acid; (S)-{5-[1-(2-Ethylthiazol-4-yl)-2-(4-sulfoaminophenyl)ethylamino]-2-methy- l-2H-[1,2,4]triazole-3-yl}carbamic acid methyl ester; 4-{(S)-2-[4-(2-methoxyphenyl)thiazol-2-ylamino)-2-[2-(thiophen-2-yl)thiaz- ol-4-yl]ethyl}phenylsulfamic acid; 4-{(S)-2-[5-(3-methoxyphenyl)oxazole-2-ylamino]-2-(2-phenylthiazole-4-yl)- ethyl}phenylsulfamic acid; (S)-4-(2-(5-Phenyl-1,3,4-thiadiazol-2-ylamino)-2-(2-phenylthiazol-4-yl)et- hyl)-phenylsulfamic acid; 4-((S)-2-(5-Propyl-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazo- l-4-yl)ethyl)phenylsulfamic acid; 4-((S)-2-(5-Benzyl-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazo- l-4-yl)ethyl)phenylsulfamic acid; 4-((S)-2-(5-(Naphthalen-1-ylmethyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thi- ophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid; 4((S)-2-(5((Methoxycarbonyl)methyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thi- ophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid; 4((S)-2-(5-((2-Methylthiazol-4-yl)methyl)-1,3,4-thiadiazol-2-ylamino)-2-(- 2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid; 4-{(S)-2-[4-(2,4-Difluorophenyl)thiazol-2-ylamino]-2-[2-(thiophen-2-yl)th- iazol-4-yl]ethyl}phenylsulfamic acid; (S)-4-{2-[4-(Ethoxycarbonyl)thiazol-2-ylamino]-2-(2-phenylthiazol-4-yl)et- hyl}phenylsulfamic acid; (S)-4-{2-[4-(2-Ethoxy-2-oxoethyl)thiazol-2-ylamino]-2-(2-phenylthiazol-4-- yl)ethyl}phenylsulfamic acid; (S)-4-{2-[4-(4-acetamidophenyl)thiazol-2-ylamino]-2-(2-phenylthiazol-4-yl- )ethyl}phenylsulfamic acid; (S)-4-[2-(4-phenylthiazol-2-ylamino)-2-(2-phenylthiazol-4-yl)ethyl]phenyl- sulfamic acid; (S)-4-{2-[4-(4-(methoxycarbonyl)phenyl)thiazol-2-ylamino]-2-(2-phenylthia- zol-4-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-[4-(Ethoxycarbonyl)thiazol-2-ylamino]-2-[2-(thiophen-2-yl)thiazo- l-4-yl]ethyl}phenylsulfamic acid; (S)-4-[2-(4-(Methoxycarbonyl)thiazol-5-ylamino)-2-(2-phenylthiazole-4-yl)- ethyl]phenylsulfamic acid; (S)-4-[2-(5-Phenyloxazol-2-ylamino)-2-(2-phenylthiazol-4-yl)ethyl]-phenyl- sulfamic acid; (S)-4-{2-[5-(4-Acetamidophenyl)oxazol-2-ylamino]-2-(2-phenylthiazol-4-yl)- ethyl}-phenylsulfamic acid; 4((S)-2-(5-(2,4-Difluorophenyl)oxazole-2-ylamino)-2-(2-phenylthiazole-4-y- l)ethyl)-phenylsulfamic acid; 4-{(S)-2-[5-(3-Methoxyphenyl)oxazol-2-ylamino]-2-[(2-thiophen-2-yl)thiazo- le-4-yl]ethyl}phenylsulfamic acid; (S)-4-[2-(4,6-Dimethylpyrimidin-2-ylamino)-2-(2-methylthiazole-4-yl)ethyl- ]phenyl-sulfamic acid; (S)-4-[2-(4-Hydroxy-6-methylpyrimidine-2-ylamino)-2-(2-methylthiazole-4-y- l)ethyl]phenylsulfamic acid; ((S)-2-(2-(3-chlorophenyl)acetamido)-2-(2-(thiophen-2-yl)oxazol-4-yl)ethy- l)phenylsulfamic acid; and {4-[2-(S)-(4-ethyloxazol-2-yl)-2-phenylacetylaminoethyl]-phenyl}sulfamic acid.

Details for Patent 8,569,348

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2029-06-06
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2029-06-06
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2029-06-06